Editing BCNU (Carmustine)
From Glioblastoma Treatments
Revision as of 20:42, 30 March 2024 by Lazy (talk | contribs) (Created page with "{{TreatmentInfo |drug_name=BCNU (Carmustine) |FDA_approval=Yes, approved for treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas |used_for=Recurrent Glioblastoma Multiforme (GBM) after radiation treatment |clinical_trial_phase=Various, given its long history of use |common_side_effects=Hepatic and pulmonary toxicity, myelosuppression |OS_without=Not specified in the provided context |OS_with=Not specified in the provided context |P...")
Warning: You are editing an out-of-date revision of this page.
If you publish it, any changes made since this revision will be lost.
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.